{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:54:01Z","timestamp":1772139241780,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006472","name":"Universitatea de Medicina \u0219i Farmacie Grigore T. Popa - Iasi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.imbio.2020.152049","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T21:08:14Z","timestamp":1606943294000},"page":"152049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression"],"prefix":"10.1016","volume":"226","author":[{"given":"Ion","family":"Antohe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Pavel","family":"Tanasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"D\u0103sc\u0103lescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lin","family":"D\u0103n\u0103il\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Titieanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6865-8883","authenticated-orcid":false,"given":"Mihaela","family":"Zlei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliu","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Sireteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petru","family":"Cianga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2020.152049_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.imbio.2020.152049_b0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrg3021","article-title":"Complex disease: ups and downs at the MHC","volume":"12","author":"Muers","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.imbio.2020.152049_b0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrg1489","article-title":"Gene map of the extended human MHC","volume":"5","author":"Horton","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.imbio.2020.152049_b0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1471-4906(01)01896-8","article-title":"The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity","volume":"22","author":"Wang","year":"2001","journal-title":"Trends Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1525-1578(10)60493-X","article-title":"The molecular pathology of primary immunodeficiencies","volume":"6","author":"Lim","year":"2004","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.imbio.2020.152049_b0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2249.2010.04197.x","article-title":"Immunotherapy prospects for acute myeloid leukaemia","volume":"161","author":"Barrett","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2017.04.004","article-title":"Mechanisms of immune tolerance in leukemia and lymphoma","volume":"38","author":"Curran","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2020.00264","article-title":"B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles","volume":"10","author":"Antohe","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imbio.2020.152049_b0045","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7\u2013H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2020.152049_b0050","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","article-title":"In acute myeloid leukemia, B7\u2013H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors","volume":"59","author":"Berthon","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imbio.2020.152049_b0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imbio.2020.152049_b0060","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/0008-5472.CAN-04-1350","article-title":"Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome","volume":"64","author":"Chamuleau","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.imbio.2020.152049_b0065","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","article-title":"Expression of functional B7\u2013H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia","volume":"11","author":"Tamura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imbio.2020.152049_b0070","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7\u2013H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.imbio.2020.152049_b0075","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2012-10-385591","article-title":"The role of B7 family molecules in hematologic malignancy","volume":"121","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2020.152049_b0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1179\/1607845414Y.0000000186","article-title":"Expression of costimulatory molecule B7\u2013H3 and its prognostic implications in human acute leukemia","volume":"20","author":"Hu","year":"2015","journal-title":"Hematology"},{"key":"10.1016\/j.imbio.2020.152049_b0085","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cam4.522","article-title":"B7\u2013H3 protein expression in acute myeloid leukemia","volume":"4","author":"Guery","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.imbio.2020.152049_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-immunol-041015-055420","article-title":"Variations in MHC Class II antigen processing and presentation in health and disease","volume":"34","author":"Unanue","year":"2016","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0095","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2011-12-399311","article-title":"Endogenous HLA class II epitopes that are immunogenic in vivo show distinct behavior toward HLA-DM and its natural inhibitor HLA-DO","volume":"120","author":"Kremer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2020.152049_b0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fimmu.2011.00042","article-title":"Antigen processing by macroautophagy for MHC presentation","volume":"2","author":"Munz","year":"2011","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2567.1999.00676.x","article-title":"Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments","volume":"96","author":"Moldenhauer","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.imbio.2020.152049_b0110","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1242\/jcs.01288","article-title":"The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment","volume":"117","author":"Dani","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.imbio.2020.152049_b0115","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00262-010-0908-z","article-title":"Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes","volume":"59","author":"van Luijn","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imbio.2020.152049_b0120","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.0501190102","article-title":"Autophagy promotes MHC class II presentation of peptides from intracellular source proteins","volume":"102","author":"Dengjel","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.imbio.2020.152049_b0125","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.1104904","article-title":"Endogenous MHC class II processing of a viral nuclear antigen after autophagy","volume":"307","author":"Paludan","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.imbio.2020.152049_b0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2005.03.009","article-title":"Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens","volume":"22","author":"Zhou","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.imbio.2020.152049_b0135","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4161\/onci.21205","article-title":"Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy","volume":"1","author":"Thibodeau","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.imbio.2020.152049_b0140","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2014.03.014","article-title":"High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia","volume":"38","author":"van den Ancker","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.imbio.2020.152049_b0145","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-10-3689","article-title":"Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells","volume":"71","author":"van Luijn","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.imbio.2020.152049_b0150","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.941737","article-title":"Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia","volume":"3","author":"van Luijn","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.imbio.2020.152049_b0155","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2020.152049_b0160","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2020.152049_b0165","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.imbio.2020.152049_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.27","article-title":"Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting","volume":"3","author":"Feller","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.imbio.2020.152049_b0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-319-53156-4_4","article-title":"Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML","volume":"995","author":"Masarova","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.imbio.2020.152049_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6040110","article-title":"Dissecting the immune landscape of acute myeloid leukemia","volume":"6","author":"Davidson-Moncada","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.imbio.2020.152049_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fimmu.2020.00121","article-title":"Neoantigens in hematologic malignancies","volume":"11","author":"Biernacki","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0190","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/sj.leu.2402742","article-title":"Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes","volume":"16","author":"Makita","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.imbio.2020.152049_b0195","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.176461","article-title":"Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition","volume":"102","author":"Greiner","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2020.152049_b0200","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4161\/onci.1.2.18100","article-title":"Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation","volume":"1","author":"van Luijn","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.imbio.2020.152049_b0205","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0210","doi-asserted-by":"crossref","first-page":"15056","DOI":"10.1073\/pnas.96.26.15056","article-title":"Extracellular antigen processing and presentation by immature dendritic cells","volume":"96","author":"Santambrogio","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.imbio.2020.152049_bib246","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1073\/pnas.96.26.15050","article-title":"Abundant empty class II MHC molecules on the surface of immature dendritic cells","volume":"96","author":"Santambrogio","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.imbio.2020.152049_b0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/1074-7613(95)90089-6","article-title":"DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide","volume":"3","author":"Sherman","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.imbio.2020.152049_b0220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90061-6","article-title":"HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading","volume":"82","author":"Denzin","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.imbio.2020.152049_b0225","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bbmt.2014.02.005","article-title":"Human leukocyte antigen-DO regulates surface presentation of human leukocyte antigen class II-restricted antigens on B cell malignancies","volume":"20","author":"Kremer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.imbio.2020.152049_b0230","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3324\/haematol.2009.010595","article-title":"Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses","volume":"95","author":"van Luijn","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2020.152049_b0235","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.imbio.2020.152049_b0240","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/eji.201242814","article-title":"Myeloid leukemia cells with a B7\u20132(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands","volume":"43","author":"Dolen","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.imbio.2020.152049_b0245","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24524","article-title":"A co-stimulatory trap set by myeloid leukemia cells","volume":"2","author":"Esendagli","year":"2013","journal-title":"Oncoimmunology"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298520305714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298520305714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:48:25Z","timestamp":1759250905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298520305714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0171298520305714"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2020.152049","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2020.152049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152049"}}